Roche: positive phase III data in Covid-19
(CercleFinance.com) - Roche confirms positive results from the phase III REGN-COV 2067 trial evaluating a treatment for high-risk outpatients with Covid-19, which has met its primary endpoint and all major secondary endpoints.
This trial has showed that the investigational antibody cocktail casirivimab-imdevimab reduced the risk of hospitalisation or death by 70% or 71% compared to placebo, in addition to reducing the duration of symptoms by four days.
In addition, a companion phase II trial (REGN-COV 20145) in symptomatic or asymptomatic, non-hospitalised, low-risk patients with Covid-19 showed significant and comparable reductions in viral load.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
This trial has showed that the investigational antibody cocktail casirivimab-imdevimab reduced the risk of hospitalisation or death by 70% or 71% compared to placebo, in addition to reducing the duration of symptoms by four days.
In addition, a companion phase II trial (REGN-COV 20145) in symptomatic or asymptomatic, non-hospitalised, low-risk patients with Covid-19 showed significant and comparable reductions in viral load.
Copyright (c) 2021 CercleFinance.com. All rights reserved.